Celldex Therapeutics, Inc. — Form 10-K Summary
Business context and reporting period. This is Celldex’s annual report for the fiscal year ended December 31, 2022, not a standalone fourth-quarter report. Celldex is a pre-commercial biopharmaceutical company developing monoclonal and bispecific antibodies for inflammatory diseases and cancer. It reported no product sales revenue and a history of operating losses.
Financial performance and position
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Total revenue | $2.4 million | $4.7 million |
| Research and development expense | $82.3 million | $53.3 million |
| General and administrative expense | $27.2 million | $20.5 million |
| Operating loss | $115.2 million | $71.2 million |
| Net loss | $112.3 million | $70.5 million |
| Net loss per share | $2.40 | $1.64 |
| Net cash used in operations | $103.7 million | $60.9 million |
- Revenue fell 49%, mainly because of lower services revenue under manufacturing and research agreements. Revenue is not a meaningful basis for assessing operating margins given the absence of product sales.
- R&D expense rose 54%, chiefly from barzolvolimab clinical trial and manufacturing activity; G&A rose 33%. Management expected both clinical and contract manufacturing costs to increase as development expanded.
- At year-end, cash, cash equivalents and marketable securities totaled $305.0 million, down from $408.3 million a year earlier. Current assets were $317.7 million and current liabilities $18.6 million; stockholders’ equity was $326.2 million.
- The balance sheet reports no outstanding term loan or other borrowings; total liabilities were $26.5 million, including lease and other liabilities. Operating cash flow was the principal cash use. Investing activities provided $89.9 million, mainly reflecting net sales and maturities of marketable securities; financing activities provided $4.1 million, primarily from employee stock plans.
Material changes, outlook and risks
- Net loss widened 59% year over year, reflecting increased R&D and G&A and a $15.0 million litigation-settlement charge. Partly offsetting these items was a $6.9 million non-cash gain from remeasurement of contingent consideration, primarily following the decision to deprioritize CDX-1140. The 2021 comparison included a $3.5 million non-cash impairment charge.
- Celldex settled its Kolltan-related litigation in 2022, paid $15.0 million, and replaced the former milestone terms. Potential future payments include a barzolvolimab Phase 2 milestone, subject to a contractual credit, and a payment upon FDA or EMA approval of a surviving product. The filing states potential future payments could total up to $65.0 million; payment may be in cash, shares, or a combination.
- Management estimated year-end liquidity would fund planned operations through 2025, including specified ongoing and planned trials. This estimate is subject to development spending, milestone timing and the ability to raise additional capital. The company said it may pursue partnering, debt or equity financing; equity could dilute shareholders and debt could bring restrictive covenants.
- Barzolvolimab is the lead program. Phase 2 studies in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) were underway. The filing also reported, as a post-year-end update in February 2023, positive interim Phase 1b CSU results; Phase 2 CSU topline data were anticipated in late 2023 or Q1 2024. Management planned a Phase 2 EoE study in the first half of 2023 and expected CDX-585 to enter clinical testing in 2023. PN study enrollment closed in February 2023, with data expected in the second half of 2023.
- Celldex discontinued CDX-527 after results did not meet internal criteria and closed enrollment; it also paused company-sponsored CDX-1140 studies while considering third-party-sponsored work. In non-human primate toxicology, barzolvolimab affected spermatogenesis, which management reported recovered during follow-up; clinical monitoring and human relevance remain important.
- Key risks include clinical-trial failure or delays, safety findings, patient enrollment, manufacturing and supply-chain constraints, regulatory approval uncertainty, competition, intellectual-property disputes, reimbursement and pricing pressure, and the need for additional capital. Management reported effective disclosure controls and internal control over financial reporting; the auditor also opined that internal controls were effective.
Most important facts for investors to verify
- Whether Phase 2 CSU and CIndU trials meet endpoints, and how interim Phase 1b CSU findings translate into controlled-trial results.
- Actual cash burn, investment balances and runway as trial scope and manufacturing spending increase; compare subsequent financing and partnering activity with management’s runway estimate.
- The timing, accounting and cash-versus-stock treatment of any Kolltan settlement milestones, including the potential dilution or cash burden.
- Safety and durability of barzolvolimab, including hematologic effects, hair or taste changes, infusion reactions, and reproductive findings from toxicology.
- Whether planned EoE, PN and CDX-585 development milestones occurred, and the implications of discontinued or deprioritized programs for pipeline focus and spending.